Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

Francis Patrick Ostronic Insider Information

Director of Cyclo Therapeutics


Mr. Ostronic is an officer of US Pharmacia International, Inc., a subsidiary of USP, and also serves as the Chief Financial Officer of The USP Group. Mr. Ostronic is also a director of Novit US, Inc., the general partner of Novit.

What is Francis Patrick Ostronic's net worth?

The estimated net worth of Francis Patrick Ostronic is at least $141,686.82 as of April 16th, 2021. Mr. Ostronic owns 71,559 shares of Cyclo Therapeutics stock worth more than $141,687 as of May 21st. This net worth evaluation does not reflect any other assets that Mr. Ostronic may own. Learn More about Francis Patrick Ostronic's net worth.

How do I contact Francis Patrick Ostronic?

The corporate mailing address for Mr. Ostronic and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected] Learn More on Francis Patrick Ostronic's contact information.

Has Francis Patrick Ostronic been buying or selling shares of Cyclo Therapeutics?

Francis Patrick Ostronic has not been actively trading shares of Cyclo Therapeutics during the last quarter. Most recently, 0 shares of the firm's stock in a transaction dated Saturday, May 21st. Learn More on Francis Patrick Ostronic's trading history.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO). Learn More on Cyclo Therapeutics' active insiders.

Are insiders buying or selling shares of Cyclo Therapeutics?

During the last twelve months, Cyclo Therapeutics insiders bought shares 17 times. They purchased a total of 70,754 shares worth more than $297,326.22. The most recent insider tranaction occured on May, 16th when COO Jeffrey Tate bought 3,000 shares worth more than $6,360.00. Insiders at Cyclo Therapeutics own 12.3 % of the company. Learn More about insider trades at Cyclo Therapeutics.

Information on this page was last updated on 5/16/2022.

Francis Patrick Ostronic Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/24/2022Buy2,000$3.75$7,500.00View SEC Filing Icon  
1/19/2022Buy1,132$4.00$4,528.00View SEC Filing Icon  
1/14/2022Buy2,137$4.00$8,548.00View SEC Filing Icon  
12/15/2021Buy3,000$3.90$11,700.00View SEC Filing Icon  
12/3/2021Buy864$4.75$4,104.00View SEC Filing Icon  
12/1/2021Buy5,000$5.00$25,000.00View SEC Filing Icon  
11/19/2021Buy10,652$5.25$55,923.00View SEC Filing Icon  
10/29/2021Buy1,000$5.90$5,900.00View SEC Filing Icon  
4/16/2021Buy10,000$6.53$65,300.0071,559View SEC Filing Icon  
4/12/2021Buy5,000$7.00$35,000.00
12/17/2020Buy30,000$4.66$139,800.00
See Full Table

Francis Patrick Ostronic Buying and Selling Activity at Cyclo Therapeutics

This chart shows Francis Patrick Ostronic's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Read More

Today's Range

Now: $1.98
Low: $1.95
High: $2.10

50 Day Range

MA: $2.68
Low: $1.98
High: $3.21

2 Week Range

Now: $1.98
Low: $1.88
High: $13.00

Volume

26,605 shs

Average Volume

54,353 shs

Market Capitalization

$16.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The Secret to Financial Freedom (True Financial Independence!)
Mark your calendar now...Thursday, June 9, at 8 p.m. ET.

That's when Bill O'Reilly will press stock-picking legend Alexander Green to reveal - for the first time ever - the secret to obtaining truly life-changing wealth in America.

You're Invited to Join FREE - Discover the Secret to True Financial Independence!
>>>